Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Feb;156(4):399-402.
doi: 10.1111/jnc.15238. Epub 2020 Dec 4.

Hippocampal hyperglutamatergic signaling matters: Early targeting glutamate neurotransmission as a preventive strategy in Alzheimer's disease: An Editorial Highlight for "Riluzole attenuates glutamatergic tone and cognitive decline in AβPP/PS1 mice" on page 513

Natalia V Gulyaeva  1   2
Affiliations
Free article
Editorial

Hippocampal hyperglutamatergic signaling matters: Early targeting glutamate neurotransmission as a preventive strategy in Alzheimer's disease: An Editorial Highlight for "Riluzole attenuates glutamatergic tone and cognitive decline in AβPP/PS1 mice" on page 513

Natalia V Gulyaeva. J Neurochem. 2021 Feb.
Free article

Abstract

This Editorial highlights a remarkable study in the current issue of the Journal of Neurochemistry in which Hascup and coworkers provide novel data showing that riluzole, an anti-glutamatergic drug, may be a promising early intervention strategy for Alzheimer's disease (AD), aimed at restoring glutamate neurotransmission prior to amyloid beta (Aβ) plaque accumulation and cognitive decline. The mice APP/PS1, a model of AD, initially are cognitively normal but have elevated glutamate release in the hippocampus at 2-4 months of age. They begin showing cognitive decline and Aβ plaque accumulation at approximately 6-8 months of age, and show obvious AD neuropathology and cognitive impairment at 10-12 months. The riluzole treatment over 4 months (at 2-6 months of age) targeting early changes in glutamatergic neurotransmission prevents cognitive decline observed at 12 months of age and restores glutamatergic neurotransmission. This is one of the most convincing preclinical evidence supporting the idea of targeting glutamate neurotransmission in patients at risk for AD and to use riluzole for this purpose.

Keywords: APP/PS1 mice; Alzheimer's disease; glutamate neurotransmission; hippocampus; riluzole.

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Bellingham, M. C. (2011). A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: What have we learned in the last decade? CNS Neuroscience & Therapeutics, 17, 4-31. https://doi.org/10.1111/j.1755-5949.2009.00116.x
    1. Erickson, J. D. (2017). Functional identification of activity-regulated, high-affinity glutamine transport in hippocampal neurons inhibited by riluzole. Journal of Neurochemistry, 142, 29-40. https://doi.org/10.1111/jnc.14046
    1. Findley, C. A., Bartke, A., Hascup, K. N., & Hascup, E. R. (2019). Amyloid beta-related alterations to glutamate signaling dynamics during Alzheimer’s disease progression. ASN Neuro, 11, 1-20. https://doi.org/10.1177/1759091419855541
    1. Hascup, E. R., Broderick, S. O., Russell, M. K., Fang, Y., Bartke, A., Boger, H. A., & Hascup, K. N. (2019). Diet-induced insulin resistance elevates hippocampal glutamate as well as VGLUT1 and GFAP expression in AβPP/PS1 mice. Journal of Neurochemistry, 148, 219-237. https://doi.org/10.1111/jnc.14634
    1. Hascup, E. R., & Hascup, K. N. (2020). Toward refining Alzheimer's disease into overlapping subgroups. Alzheimer's & Dementia: the Journal of the Alzheimer's Association, N. Y.). 6, e12070, https://doi.org/10.1002/trc2.12070

LinkOut - more resources